Unibest

Pharmaceutical intermediates

Trilaciclib hydrochloride Intermediates

2 pharmaceutical intermediates for Trilaciclib hydrochloride. Indication: Chemotherapy-Induced Myelosuppression.

提交项目All intermediates

About Trilaciclib hydrochloride

Originator
G1 Therapeutics Inc
Indication
Chemotherapy-Induced Myelosuppression
Approved Date
02/12/2021
NCE Patent
10/25/2031
DS/DP
02/12/2026

Available intermediates

2 intermediates currently listed for Trilaciclib hydrochloride. Request specifications, documentation or a quotation for any item below.

Trilaciclib hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Spiro[cyclohexane-1,9'(6'H)-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidine]-7'(8'H)-carboxylic acid, 2'-(methylthio)-6'-oxo-, 1,1-dimethylethyl ester2170746-99-1//
1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE571189-49-6//

Other programs under T

Tazemetostat HydrobromideTazobactam SodiumTegoprazanTenapanor HydrochlorideTeneligliptinTetrabenazineTezacaftorTianeptine sodium salt

Building toward Trilaciclib hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →